在预治疗时识别多发性肝细胞癌CT:跨动脉化学栓塞后治疗结果的影响

Yan Bao1, Jun-Xiang Li1, Peng Zhou1

  • 1From the Departments of Radiology (Y.B., Y.T., J.L., Y.D.X.), Pathology (P.Z.), and Liver Surgery (W.W.C.), the Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Rd, Changsha 410011, China; Department of Interventional Radiology, the Affiliated Cancer Hospital of Guizhou Medical University, Guiyang, China (J.X.L.); Department of Interventional Radiology, the Affiliated Hospital of Guizhou Medical University, Guiyang, China (L.Z.W.); Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany (D.H.C.); and Department of Diagnostic Radiology, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China (L.W.).

Radiology
|August 29, 2023
PubMed
概括

一种新的CT成像模型,即SMARS评分,可以识别多发性肝细胞癌 (HCC). 这种模型有助于预测哪些HCC患者在化学栓塞治疗后会出现更糟糕的结果.